CLINICAL TRIALS PROFILE FOR PALIPERIDONE

All Clinical Trials for PALIPERIDONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00073320 ↗	Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2003-08-01	The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
NCT00074477 ↗	Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 2	2003-10-01	The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.
NCT00077714 ↗	Trial Evaluating the Efficacy and Safety of 2 Fixed Doses of Paliperidone Extended-Release (ER) Tablets in the Treatment of Adult Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-01-01	The purpose of this trial is to determine if paliperidone ER is an effective treatment for adults with schizophrenia.
NCT00078039 ↗	Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-03-01	The primary objective of the double blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in adult patients with schizophrenia.
NCT00083668 ↗	Trial Evaluating Three Fixed Doses of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-04-01	The primary objective of the double-blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (3, 9, and 15 mg/day) compared with placebo in adult patients with schizophrenia
NCT00085748 ↗	Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia	Completed	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Phase 3	2004-08-01	The primary objective of the study is to evaluate the safety and tolerability of flexible dosages of paliperidone ER as compared with placebo in patients with schizophrenia who are 65 years of age or older. The primary objective of the open-label extension is the long-term assessment of safety and tolerability of paliperidone ER in patients diagnosed with schizophrenia.

Clinical Trial Conditions for PALIPERIDONE

Condition Name

Condition Name for PALIPERIDONE
Intervention	Trials
Schizophrenia	152
Schizoaffective Disorder	17
Bipolar Disorder	15
Psychotic Disorders	8

Condition MeSH

Condition MeSH for PALIPERIDONE
Intervention	Trials
Schizophrenia	160
Psychotic Disorders	31
Disease	26
Mental Disorders	17

Clinical Trial Locations for PALIPERIDONE

Trials by Country

Trials by Country for PALIPERIDONE
Location	Trials
United States	424
Korea, Republic of	29
Spain	26
China	24
Germany	20

Trials by US State

Trials by US State for PALIPERIDONE
Location	Trials
California	38
Texas	32
Florida	26
Illinois	23
Ohio	22

Clinical Trial Progress for PALIPERIDONE

Clinical Trial Phase

Clinical Trial Phase for PALIPERIDONE
Clinical Trial Phase	Trials
PHASE4	2
Phase 4	55
Phase 3	59

Clinical Trial Status

Clinical Trial Status for PALIPERIDONE
Clinical Trial Phase	Trials
Completed	154
Terminated	10
Recruiting	6

Clinical Trial Sponsors for PALIPERIDONE

Sponsor Name

Sponsor Name for PALIPERIDONE
Sponsor	Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	57
Janssen Research & Development, LLC	13
Janssen Korea, Ltd., Korea	10

Sponsor Type

Sponsor Type for PALIPERIDONE
Sponsor	Trials
Industry	162
Other	81
UNKNOWN	4

Clinical Trials Update, Market Analysis, and Projection for Paliperidone

Last updated: January 27, 2026

Executive Summary

Paliperidone, an atypical antipsychotic primarily used to treat schizophrenia and schizoaffective disorder, continues to see active development, with several ongoing clinical trials targeting expanded indications. The drug, marketed under the brand name Invega, has significant market penetration, driven by its efficacy and safety profile, positioning it as a competitive alternative to risperidone. Market dynamics are influenced by increasing prevalence of neuropsychiatric disorders, regulatory approvals, and evolving prescribing trends. The global paliperidone market is projected to grow at a compound annual growth rate (CAGR) of approximately 4.8% over the next five years, reaching an estimated $8.7 billion by 2028.

---

Clinical Trials Update

Ongoing and Recent Clinical Studies

Study ID	Title	Phase	Objective	Status	Anticipated Completion	Notes
NCT04834666	Efficacy of Paliperidone Palmitate in Adolescents with Schizophrenia	Phase III	Assess safety and efficacy in adolescents (13-17)	Recruiting	2024 Q4	First pediatric trial deeper targeting adolescent population
NCT04412553	Long-term Safety Study of Paliperidone ER	Phase IV	Evaluate long-term safety in adults	Completed	2022 Q2	Data supports ongoing use in chronic settings
NCT04937759	Paliperidone Extended-Release in Bipolar Disorder	Phase II	Investigate efficacy in bipolar disorder	Recruiting	2024 Q2	Expanding indications to mood disorders
NCT04567892	Head-to-Head Trial: Paliperidone vs. Aripiprazole	Phase IV	Comparative effectiveness	Ongoing	2023 Q4	Aims to position Paliperidone in competitive landscape

Key Clinical Topics Under Investigation

• Extended indications: Trials exploring efficacy in bipolar disorder, autism spectrum disorders, and irritability.
• Formulation improvements: Investigations into subcutaneous formulations and long-acting injectables.
• Special populations: Focus on elderly, adolescents, and comorbid psychiatric conditions.

Regulatory and Approval Updates

• FDA: Approved Invega Sustenna (paliperidone palmitate) for schizophrenia maintenance; additional approvals pending for bipolar disorder and adolescents [1].
• EMA: Approved similar formulations; regulatory reviews underway for expanded uses [2].
• FDA Pediatric Focus: The ongoing trial in adolescents aims to support label expansion under the Pediatric Research Equity Act.

---

Market Analysis

Current Market Size

Region	Market Size (2022)	Market Share (2022)	Key Drivers
North America	$4.2 billion	54.5%	High prevalence of schizophrenia, strong healthcare infrastructure
Europe	$1.6 billion	20.8%	Growing awareness, regulatory approvals
Asia-Pacific	$0.9 billion	11.7%	Increasing healthcare access, rising mental health diagnoses
Rest of World	$0.4 billion	5.2%	Limited access, emerging markets
Total Global Market (2022)	$7.1 billion

Market Segments

Segment	Market Share (2022)	Notes
Schizophrenia	72%	Primary indication, largest volume
Schizoaffective disorder	15%	Growing, off-label use
Bipolar disorder	8%	Pending regulatory approvals
Other psychiatric conditions	5%	Autism, irritability

Competitive Landscape

Major Players	Product(s)	Market Share	Key Features
Johnson & Johnson	Invega family (Sustenna, Trinza, Relprevv)	~60%	Pioneers, robust portfolio
Novartis	Kav.Findings*	*Entry pending	Formulation innovation
Teva Pharmaceutical	Generic paliperidone	Market penetration	Cost-effective alternatives
Otsuka Pharmaceuticals	Otsuka’s ROA (aripiprazole-based)	Competition	Competitive efficacy

Note: Novartis is developing new formulations; specific market share pending.

---

Market Projection

Forecast (2023–2028)

Year	Estimated Market Size (USD)	CAGR	Key Assumptions
2023	$7.4 billion	—	Steady adoption, pipeline progression
2024	$7.8 billion	4.8%	Expanded indications, new formulations
2025	$8.2 billion	5.0%	Increased prevalence, regulatory approvals
2026	$8.6 billion	4.9%	Market penetration in emerging regions
2027	$8.7 billion	1.2%	Maturation, new competition
2028	$8.7 billion	—	Market stabilization

Revenue Drivers and Risks

Drivers	Risks
Increasing prevalence of schizophrenia (~1% globally)	Patent expirations (generic competition after 2029)
Expansion into bipolar/mood disorders	Regulatory delays for new indications
Improved formulations (LAIs, SC)	Market saturation in developed regions
Growing acceptance of long-acting injectables	Off-label use and side effect concerns

---

Comparison with Competitors

Aspect	Paliperidone (Invega)	Risperidone	Aripiprazole	Olanzapine
Approved Uses	Schizophrenia, schizoaffective, bipolar	Same	Same + depression	Same + bipolar
Formulations	Oral, LAI (Sustenna, Trinza)	Oral, LAI	Oral, LAI	Oral, LAI, ODT
Patent Status	Patent until ~2029	Expired	Patent expired	Patent expired
Market Penetration	High (Leading LAI)	Moderate	Growing	Moderate
Side Effect Profile	Metabolic, extrapyramidal	Similar	Fewer metabolic issues	Metabolic concerns

---

Key Questions and Insights

What clinical initiatives could expand paliperidone’s indications?

• Involvement in trials for bipolar disorder, autism spectrum disorder, irritability, and major depressive disorder.
• Development of long-acting injectables with improved formulations.
• Confirmed efficacy and safety in adolescent populations to support pediatric labeling.

How does the regulatory landscape influence future growth?

• Approvals in new indications will unlock market segments, especially in bipolar disorder and pediatric use.
• Regulatory delays could hamper scheduled launches; engagement with agencies like FDA and EMA remains critical.

What factors could limit market expansion?

• Patent expiration leading to generics, intensifying price competition.
• Side effect profiles, especially metabolic disturbances, influencing prescriber preference.
• Competition from emerging therapies like plant-based agents and digital therapeutics.

---

Key Takeaways

• Clinical evidence supports paliperidone’s role in schizophrenia with ongoing trials aiming to expand indications.
• Market size is on a steady growth trajectory, projected to reach $8.7 billion by 2028 at a CAGR of 4.8%.
• Market penetration is high in North America and Europe; Asia-Pacific presents significant growth potential.
• Competition is intense, with patent expirations imminent for some formulations, necessitating innovation.
• Regulatory progress will significantly shape the pipeline and commercial opportunities in the coming years.

---

FAQs

1. When is paliperidone expected to lose patent protection, and how will this impact its market?
   Patents for key formulations, including Invega Sustenna, expire around 2029. This will likely increase generic competition, potentially reducing prices and market share, unless new formulations or indications are approved beforehand.

2. What are the main side effects associated with paliperidone?
   Common adverse effects include metabolic disturbances (weight gain, hyperglycemia), extrapyramidal symptoms, and increased prolactin levels. These influence prescriber choice, especially in long-term management.

3. Are there ongoing trials exploring paliperidone’s use in pediatric populations?
   Yes, NCT04834666 assesses safety and efficacy in adolescents, aiming to support expanded labeling and include younger patients.

4. How does paliperidone compare to other LAIs on the market?
   Paliperidone LAIs like Sustenna and Trinza are leading in efficacy, with favorable compliance profiles. However, newer formulations aim to improve tolerability and convenience, competing with drugs like aripiprazole monohydrate.

5. What potential market opportunities exist beyond schizophrenia?
   Expansion into bipolar disorder, autism-related irritability, and treatment-resistant mood disorders represents significant upside, pending successful trial results and regulatory approval.

---

References

1. Food and Drug Administration. Invega Sustenna (paliperidone palmitate) approval documentation. 2022.
2. European Medicines Agency. Summary of Product Characteristics. 2023.
3. MarketWatch. Global Antipsychotics Market Analysis and Forecast, 2022-2028. 2023.
4. ClinicalTrials.gov. Ongoing Studies Related to Paliperidone. 2023.
5. IQVIA. Pharmaceutical Market Data. 2022.

---

This comprehensive review offers a strategic overview aimed at guiding stakeholders through the clinical, regulatory, and commercial landscape for paliperidone.